<DOC>
	<DOCNO>NCT00928889</DOCNO>
	<brief_summary>This study conduct demonstrate superiority nateglinide postprandial glucose fluctuation , dyslipidemia , inflammatory status improvement .</brief_summary>
	<brief_title>Effects Nateglinide v Acarbose Postprandial Glucose Fluctuation , Dyslipidemia , Inflammatory Factors</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Acarbose</mesh_term>
	<mesh_term>Nateglinide</mesh_term>
	<criteria>Newly diagnose type 2 diabetes mellitus patient HbA1c &gt; 6.5 &lt; 9.0 % Fasting fingertip capillary blood glucose ( FCBG ) &lt; 9 mmol/L 2 week diet control History acute metabolic complication past 3 month severe diabetic complication severe infection active substance abuse Liver disease Patients oral hypoglycemic drug and/or insulin treatment , corticosteroid treatment within past 4 week Other protocoldefined inclusion/exclusion criterion apply study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>diabetes mellitus , type 2</keyword>
	<keyword>nateglinide</keyword>
	<keyword>acarbose</keyword>
	<keyword>hyperglycemia</keyword>
	<keyword>dyslipidemias</keyword>
	<keyword>C-reactive protein</keyword>
</DOC>